8x8 Inc vs Tilray Brands Inc — how do they compare? 8x8 Inc trades at $2.13 (market cap $311.98M), while Tilray Brands Inc trades at $3.49 (market cap $530.54M). The key difference: Tilray Brands Inc is the larger of the two by market cap, and 8x8 Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and Tilray Brands Inc for 31 Days on average.
| EGHT | TLRY | |
|---|---|---|
Market Cap | $311.98M | $530.54M |
Volume | 1,639,086 | 9,099,075 |
Sector | Technology | Health |
52-Week High | $2.76 | $21.00 |
52-Week Low | $1.59 | $3.57 |
Typical Hold Time | 16 Days | 31 Days |
Enterprise Value | $578.90M | $684.46M |
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.15, up 0.47% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $27.21M in 2025 but shows improving trends with revenue growth to $745M and a projected net profit of $5M in 2026. Recent news highlights cost-saving client wins and AI product growth, while analyst consensus is a Buy with a $19.77 price target, suggesting significant upside potential from current levels.
The outlook is cautiously optimistic, with earnings beats and projected profitability offering opportunity, but high debt and thin margins pose risks. Investor sentiment is mixed amid valuation concerns, yet institutional interest and strategic partnerships support a positive long-term view if execution improves.
TLRY trades at $3.465, down 6.73% on the day and near 52-week lows, reflecting persistent bearish sentiment. The stock shows weak technical momentum with oversold RSI readings but faces fundamental challenges including consecutive quarterly earnings misses, negative profit margins, and declining revenue growth. Recent news highlights the company's struggles with profitability despite record annual revenue, with shares down over 50% year-to-date as investors question the cannabis company's path to sustainable growth.
TLRY presents a high-risk opportunity with significant downside protection from its low P/B ratio of 0.33, but requires substantial operational improvement to justify investment. The bullish case hinges on potential marijuana reform catalysts and BrewDog integration progress, while risks include ongoing losses, competitive pressures, and execution challenges in a volatile regulatory environment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →